Want to join the conversation?
$GILD 2Q15 Call: Pleased with the number of patients GILD is reaching with Sovaldi and Harvoni, which are now approved in 51 and 40 countries, respectively. Total HCV revenue was $4.9Bil. US HCV product revenue was $3.4Bil, of which Harvoni represented $2.8Bil. In 1H15, estimated 130K US hepatitis C patients started treatment on a Gilead product.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?